News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Trius Therapeutics (TSRX) Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin



5/13/2013 9:47:18 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, May 13, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious infections, announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) on an application related to its tedizolid phosphate patent portfolio. This newly allowed patent application protects a therapeutic combination of the experimental medicine tedizolid phosphate with a currently available antibiotic daptomycin. Data show that together, the medicines can uniquely prevent the development of daptomycin non-susceptible bacterial strains such as methicillin-resistant Staphylococcus aureus (MRSA).

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES